{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=15&state=Michigan",
    "query": {
      "state": "Michigan",
      "city": "Detroit",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 7238,
    "total_pages": 724,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=16&state=Michigan&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=14&state=Michigan&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T20:04:29.841Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00234039",
      "title": "S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 58,
      "start_date": "2006-11",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2016-01-08",
      "last_synced_at": "2026-10-28T20:04:29.841Z",
      "location_count": 98,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Leesburg, Florida + 56 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Leesburg",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00234039"
    },
    {
      "nct_id": "NCT00910039",
      "title": "Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cognitive/Functional Effects",
        "Metastatic Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        },
        {
          "name": "cognitive assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2009-04",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2014-09-29",
      "last_synced_at": "2026-10-28T20:04:29.841Z",
      "location_count": 3,
      "location_summary": "Detroit, Michigan • Cleveland, Ohio",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00910039"
    },
    {
      "nct_id": "NCT06071377",
      "title": "Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sickle Cell Trait"
      ],
      "interventions": [
        {
          "name": "Biologic Specimen Collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "National Alliance for Sickle Cell Centers",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2023-04-01",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-28T20:04:29.841Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Wilmington, Delaware • Indianapolis, Indiana + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06071377"
    },
    {
      "nct_id": "NCT01808573",
      "title": "A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HER2+ Metastatic Breast Cancer (MBC)"
      ],
      "interventions": [
        {
          "name": "neratinib",
          "type": "DRUG"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "lapatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Puma Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 621,
      "start_date": "2013-03-29",
      "completion_date": "2019-12-09",
      "has_results": true,
      "last_update_posted_date": "2021-06-11",
      "last_synced_at": "2026-10-28T20:04:29.841Z",
      "location_count": 79,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 56 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Alhambra",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01808573"
    },
    {
      "nct_id": "NCT03258554",
      "title": "Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Head and Neck Squamous Cell Carcinoma",
        "Hypopharyngeal Squamous Cell Carcinoma",
        "Laryngeal Squamous Cell Carcinoma",
        "Oral Cavity Squamous Cell Carcinoma",
        "Oropharyngeal Squamous Cell Carcinoma",
        "Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Squamous Cell Carcinoma of Unknown Primary",
        "Stage III Hypopharyngeal Carcinoma AJCC v8",
        "Stage III Laryngeal Cancer AJCC v8",
        "Stage III Lip and Oral Cavity Cancer AJCC v8",
        "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage IVA Hypopharyngeal Carcinoma AJCC v8",
        "Stage IVA Laryngeal Cancer AJCC v8",
        "Stage IVA Lip and Oral Cavity Cancer AJCC v8",
        "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage IVB Hypopharyngeal Carcinoma AJCC v8",
        "Stage IVB Laryngeal Cancer AJCC v8",
        "Stage IVB Lip and Oral Cavity Cancer AJCC v8",
        "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 196,
      "start_date": "2018-04-03",
      "completion_date": "2025-09-04",
      "has_results": true,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-10-28T20:04:29.841Z",
      "location_count": 252,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 193 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03258554"
    },
    {
      "nct_id": "NCT05541822",
      "title": "To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Vabametkib",
          "type": "DRUG"
        },
        {
          "name": "Lazertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abion Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2023-01-17",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2025-05-22",
      "last_synced_at": "2026-10-28T20:04:29.841Z",
      "location_count": 4,
      "location_summary": "Lake City, Florida • Orange City, Florida • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Lake City",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05541822"
    },
    {
      "nct_id": "NCT00494351",
      "title": "Study on the Effect of NdYag Laser for the Treatment of Hidradenitis Suppurativa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Long-pulsed Nd:YAG laser 1064 nm",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2007-06",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2024-04-30",
      "last_synced_at": "2026-10-28T20:04:29.841Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00494351"
    },
    {
      "nct_id": "NCT02756845",
      "title": "Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Non CNS Tumors"
      ],
      "interventions": [
        {
          "name": "Talimogene Laherparepvec",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 15,
      "start_date": "2017-08-16",
      "completion_date": "2022-11-29",
      "has_results": true,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-10-28T20:04:29.841Z",
      "location_count": 9,
      "location_summary": "Wilmington, Delaware • Jacksonville, Florida • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02756845"
    },
    {
      "nct_id": "NCT03337477",
      "title": "A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperkalemia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Sodium Zirconium Cyclosilicate(ZS)",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        },
        {
          "name": "Glucose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 70,
      "start_date": "2018-02-13",
      "completion_date": "2018-12-21",
      "has_results": true,
      "last_update_posted_date": "2020-01-28",
      "last_synced_at": "2026-10-28T20:04:29.841Z",
      "location_count": 12,
      "location_summary": "Montgomery, Alabama • Phoenix, Arizona • Detroit, Michigan + 7 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03337477"
    },
    {
      "nct_id": "NCT00088166",
      "title": "XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Brain Edema",
        "Brain Tumor"
      ],
      "interventions": [
        {
          "name": "hCRF",
          "type": "DRUG"
        },
        {
          "name": "placebo hCRF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celtic Pharma Development Services",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2004-05",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2014-08-13",
      "last_synced_at": "2026-10-28T20:04:29.841Z",
      "location_count": 27,
      "location_summary": "Phoenix, Arizona • Fresno, California • Newport Beach, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00088166"
    }
  ]
}